MXPA05012299A - Composicion farmaceutica que comprende valsartan. - Google Patents

Composicion farmaceutica que comprende valsartan.

Info

Publication number
MXPA05012299A
MXPA05012299A MXPA05012299A MXPA05012299A MXPA05012299A MX PA05012299 A MXPA05012299 A MX PA05012299A MX PA05012299 A MXPA05012299 A MX PA05012299A MX PA05012299 A MXPA05012299 A MX PA05012299A MX PA05012299 A MXPA05012299 A MX PA05012299A
Authority
MX
Mexico
Prior art keywords
valsartan
pharmaceutical composition
reducing
pharmaceutically acceptable
morbidity
Prior art date
Application number
MXPA05012299A
Other languages
English (en)
Spanish (es)
Inventor
Gianni Tognoni
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA05012299A publication Critical patent/MXPA05012299A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA05012299A 2003-05-16 2004-05-14 Composicion farmaceutica que comprende valsartan. MXPA05012299A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47113703P 2003-05-16 2003-05-16
PCT/EP2004/005204 WO2004101535A1 (en) 2003-05-16 2004-05-14 Pharmaceutical composition comprising valsartan

Publications (1)

Publication Number Publication Date
MXPA05012299A true MXPA05012299A (es) 2006-01-30

Family

ID=33452429

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012299A MXPA05012299A (es) 2003-05-16 2004-05-14 Composicion farmaceutica que comprende valsartan.

Country Status (10)

Country Link
US (2) US20070054947A1 (https=)
EP (1) EP1631556A1 (https=)
JP (1) JP4783733B2 (https=)
CN (1) CN1816533A (https=)
AU (2) AU2004238546A1 (https=)
BR (1) BRPI0410374A (https=)
CA (1) CA2525665A1 (https=)
MX (1) MXPA05012299A (https=)
TW (1) TW200509909A (https=)
WO (1) WO2004101535A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080066776A (ko) * 2005-11-08 2008-07-16 노파르티스 아게 안지오텐신 ⅱ 수용체 봉쇄제, 칼슘 채널 봉쇄제 및 다른활성 약제의 조합물
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP3178812A1 (en) * 2010-11-12 2017-06-14 Hetero Research Foundation Novel polymorphs of pitavastatin calcium
WO2013147137A1 (ja) * 2012-03-30 2013-10-03 味の素株式会社 心不全の治療剤
AU2013304949C1 (en) 2012-08-24 2020-12-24 Novartis Ag NEP inhibitors for treating diseases characterized by atrial enlargement or remodeling
ES2968541T3 (es) * 2013-08-26 2024-05-10 Novartis Ag Tratamiento de enfermedades cardiovasculares
CN106414416B (zh) * 2014-09-09 2020-03-27 上海翰森生物医药科技有限公司 结晶型ARB-NEPi复合物及其制备方法和应用
WO2019241519A1 (en) * 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
WO2019241590A1 (en) * 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition
CN115317478B (zh) * 2022-08-26 2023-05-02 宁波大学 沙库巴曲缬沙坦类物质在制备药物成瘾和复吸药物的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6201002B1 (en) * 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
US6204281B1 (en) * 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
TR200100062T2 (tr) * 1998-07-10 2001-06-21 Novartis Ag Valsartan ve kalsiyum kanalı bloklayıcısının anti-hipertensif kombinasyonu
US6596747B2 (en) * 1998-10-29 2003-07-22 Bristol-Myers Squibb Company Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
CA2360305A1 (en) * 1999-02-09 2000-08-17 Bristol-Myers Squibb Company Lactam inhibitors of fxa and method
US6395728B2 (en) * 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
US6544981B2 (en) * 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
PE20020617A1 (es) * 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
EP1332131A2 (en) * 2000-11-07 2003-08-06 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
WO2002053161A1 (en) * 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
US6395782B1 (en) * 2001-03-02 2002-05-28 Wisconsin Alumni Research Foundation Method of increasing longevity and preventing body weight wasting in autoimmune disease by using conjugated linoleic acid
EP1406611A2 (en) * 2001-05-30 2004-04-14 Alteon, Inc. Method for treating fibrotic diseases or other indications
JP2005509631A (ja) * 2001-10-18 2005-04-14 ノバルティス アクチエンゲゼルシャフト Ａｔ１−レセプターアンタゴニストと心臓血管薬から形成される塩
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds

Also Published As

Publication number Publication date
WO2004101535A1 (en) 2004-11-25
AU2004238546A1 (en) 2004-11-25
CN1816533A (zh) 2006-08-09
AU2008246267A1 (en) 2008-12-11
AU2008246267B2 (en) 2011-02-17
US20070054947A1 (en) 2007-03-08
US20090105322A1 (en) 2009-04-23
TW200509909A (en) 2005-03-16
BRPI0410374A (pt) 2006-06-13
CA2525665A1 (en) 2004-11-25
EP1631556A1 (en) 2006-03-08
JP2006528949A (ja) 2006-12-28
JP4783733B2 (ja) 2011-09-28

Similar Documents

Publication Publication Date Title
NL300889I2 (nl) Trifluridine in combinatie met tipiracilhydrochloride
NO330947B1 (no) Anvendelse av farmasoytiske sammensetninger som inneholder okskarbazepin, i fastende tilstand
WO2004112711A3 (en) Oral extended-release composition
WO2000078294A3 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
HUP0401174A3 (en) Ecteinascidin analogues, their use in the preparation of a medicament for treatment of cancer and pharmaceutical compositions containing the compounds
DE60327843D1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
NZ605469A (en) Nalbuphine-based formulations and uses thereof
IL158668A0 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
MXPA05012299A (es) Composicion farmaceutica que comprende valsartan.
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2005039554A3 (en) Therapeutic use of methionine for the treatment or prevention of mucositis
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
CA2385755A1 (en) Prevention of colorectal cancer
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.
PL371741A1 (en) A combination treatment for acute myocardial infarction
FI20011464A0 (fi) Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
NZ523606A (en) Pharmaceutical compositions and methods for use
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
PT1534296E (pt) UTILIZAÇÃO DE CILOBRADINA OU DOS SEUS SAIS FARMACEUTICAMENTE ACEITÁVEIS PARA O TRATAMENTO OU PREVENÇÃO DA INSUFICIjNCIA CARDÍACA
GB9930077D0 (en) Medicaments
EA200801890A1 (ru) Средство для лечения шума в ушах
WO2005120518A3 (en) Use of atp analogues for treatment of cardiovascular diseases
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
MXPA05009849A (es) Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2.